Global Ulcerative Colitis Market, Forecast Till 2025

  • Category : Healthcare and Pharma
  • |
  • ID : 851401
  • |
  • Date : March 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Ulcerative Colitis Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Increasing prevalence of ulcerative colitis disease are the major factors driving the growth of market.

The global Ulcerative Colitis market is driven by high prevalence of ulcerative colitis disease around the world. Moreover, healthcare infrastructural advancements and expansion of drug development sector, and favorable insurance schemes, is expected to increase the demand for Ulcerative Colitis market.

Factors, such as patent expiry of drugs and stringent government regulations towards approval of biosimilars can restrain the market growth.

Introduction of new treatments, rise in R&D investment done by industries towards development of novel therapies for UC treatment and rise in government and non-government organizations towards research in biologics will offer lucrative opportunities.

Based on Route of Administration, the Ulcerative Colitis market is segmented into Oral, and Injectable.

Based on Disease Type, the Ulcerative Colitis market is segmented into Mild Ulcerative Colitis, Moderate Ulcerative Colitis, and Severe Ulcerative Colitis.

Regionally, North America was the largest revenue generator in the Ulcerative Colitis market in 2017, because of high investments in research and development activities to investigate the applications of Ulcerative Colitis market.

Some of the key players operating in this market include Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Co., Sanofi Aventis A/S, AstraZeneca plc, Merck & Co., Inc., InDex Pharmaceuticals Holding AB, Ajinomoto Pharmaceuticals Co., Ltd., and Abbott Laboratories among others.

Key Benefits of the Report:
* Global, Regional, Country, Route of Administration, and Disease Type Market Size and Forecast from 2014-2025
* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies
* Identification of key companies that can influence this market on a global and regional scale
* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies
* Detailed insights on emerging regions, Route of Administration& Disease Type, and competitive landscape with qualitative and quantitative information and facts

Target Audience:
* Ulcerative Colitis providers
* Traders, Importer and Exporter
* Raw material suppliers and distributors
* Research and consulting firms
* Government and research organizations
* Associations and industry bodies

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics, capacity Disease Type, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.
The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:
* Original Manufacturer,
* Route of Administration Supplier,
* Distributors,
* Government Body & Associations, and
* Research Institute

TABLE OF CONTENT

EXECUTIVE SUMMARY

1. METHODOLOGY AND MARKET SCOPE
1.1. Research Methodology
1.2. Research Scope & Assumptions

2. GLOBAL ULCERATIVE COLITIS MARKET — INDUSTRY OUTLOOK
2.1. Market Segmentation and Scope
2.2. Market Size & Growth Prospects
2.3. Ulcerative Colitis Market — Value Chain / Supply Chain Analysis
2.3.1. Company Landscape
2.4. Ulcerative Colitis Market — Market Dynamics
2.4.1. Market Driver
2.4.2. Market Restraints
2.4.3. Market Challenges
2.5. Ulcerative Colitis Market Company Market Share, 2017
2.6. Ulcerative Colitis Market — Porter\'s Five Forces Analysis
2.7. Ulcerative Colitis Market — Pestel Analysis

3. GLOBAL ULCERATIVE COLITIS MARKET TYPE OUTLOOK
3.1. Ulcerative Colitis Market Share by Disease Type, 2017 & 2025
3.2. Mild Ulcerative Colitis
3.3. Moderate Ulcerative Colitis
3.4. Severe Ulcerative Colitis

4. GLOBAL ULCERATIVE COLITIS MARKET ROUTE OF ADMINISTRATION OUTLOOK
4.1. Ulcerative Colitis Market Share By Route of Administration, 2017 & 2025
4.2. Oral
4.3. Injectable

5. GLOBAL ULCERATIVE COLITIS MARKET REGIONAL OUTLOOK
5.1. Ulcerative Colitis Market Share by Region, 2017 & 2025
5.2. North America
5.2.1. North America Ulcerative Colitis Market, 2014 - 2025
5.2.2. North America Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.2.3. North America Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.2.4. U.S.
5.2.4.1. U.S. Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.2.4.2. U.S. Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.2.5. Canada
5.2.5.1. Canada Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.2.5.2. Canada Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.3. Europe
5.3.1. Europe Ulcerative Colitis Market, 2014 - 2025
5.3.2. Europe Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.3.3. Europe Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.3.4. Germany
5.3.4.1. Germany Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.3.4.2. Germany Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.3.5. UK
5.3.5.1. UK Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.3.5.2. UK Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.4. Asia Pacific
5.4.1. Asia Pacific Ulcerative Colitis Market, 2014 - 2025
5.4.2. Asia Pacific Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.4.3. Asia Pacific Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.4.4. Australia
5.4.4.1. Australia Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.4.4.2. Australia Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.4.5. New Zealand
5.4.5.1. New Zealand Ulcerative Colitis Market, By Disease Type, 2014 -
2025
5.4.5.2. New Zealand Ulcerative Colitis Market, By Route of Administration, 2014 -2025
5.4.5.3. New Zealand Ulcerative Colitis Market, By End-Use, 2014 -2025
5.4.6. China
5.4.6.1. China Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.4.6.2. China Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.4.7. India
5.4.7.1. India Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.4.7.2. India Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.4.8. Japan
5.4.8.1. Japan Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.4.8.2. Japan Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.5. South America
5.5.1. South America Ulcerative Colitis Market, 2014 - 2025
5.5.2. South America Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.5.3. South America Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.5.4. Brazil
5.5.4.1. Brazil Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.5.4.2. Brazil Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.5.5. Mexico
5.5.5.1. Mexico Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.5.5.2. Mexico Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.6. MEA
5.6.1. MEA Ulcerative Colitis Market, 2014 - 2025
5.6.2. MEA Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.6.3. MEA Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.6.4. Saudi Arabia
5.6.4.1. Saudi Arabia Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.6.4.2. Saudi Arabia Ulcerative Colitis Market, By Route of Administration, 2014 - 2025
5.6.5. Egypt
5.6.5.1. Egypt Ulcerative Colitis Market, By Disease Type, 2014 - 2025
5.6.5.2. Egypt Ulcerative Colitis Market, By Route of Administration, 2014 - 2025

6. COMPETITIVE LANDSCAPE

6.1. GlaxoSmithKline plc
6.1.1. Company overview
6.1.2. Financial performance
6.1.3. Product benchmarking
6.1.4. Strategic initiatives
6.2. Sanofi Aventis A/S
6.2.1. Company overview
6.2.2. Financial performance
6.2.3. Product benchmarking
6.2.4. Strategic initiatives
6.3. Johnson & Johnson
6.3.1. Company overview
6.3.2. Financial performance
6.3.3. Product benchmarking
6.3.4. Strategic initiatives
6.4. InDex Pharmaceuticals Holding AB
6.4.1. Company overview
6.4.2. Financial performance
6.4.3. Product benchmarking
6.4.4. Strategic initiatives
6.5. Eli Lilly & Company
6.5.1. Company overview
6.5.2. Financial performance
6.5.3. Product benchmarking
6.5.4. Strategic initiatives
6.6. AstraZeneca
6.6.1. Company overview
6.6.2. Financial performance
6.6.3. Product benchmarking
6.6.4. Strategic initiatives
6.7. Ajinomoto Pharmaceuticals Co., Ltd
6.7.1. Company overview
6.7.2. Financial performance
6.7.3. Product benchmarking
6.7.4. Strategic initiatives
6.8. Merck & Co., Inc
6.8.1. Company overview
6.8.2. Financial performance
6.8.3. Product benchmarking
6.8.4. Strategic initiatives
6.9. Abbott Laboratories
6.9.1. Company overview
6.9.2. Financial performance
6.9.3. Product benchmarking
6.9.4. Strategic initiatives

End of the report
Disclaimer.





Content are not available

Choose License Type